Business
Agreement with KCA Deutag Group
Agreement with KCA Deutag Group.
About this update from Clean Power Hydrogen Plc
[{"type":"text","content":"\n \n \n \n The information communicated within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 which is part of UK law by virtue of the European Union (withdrawal) Act 2018. Upon the publication of this announcement, this inside information is now considered to be in the public domain.\n \n \n \n \n \n \n \n 05 September 2022\n \n \n \n \n \n \n \n \n \n Clean Power Hydrogen Plc\n \n \n \n \n (\"CPH2\", the \"Company\" or the \"Group\")\n \n \n \n \n Agreement with KCA Deutag Group\n \n \n \n CPH2, the UK-based green hydrogen technology and manufacturing company that has developed the IP-protected Membrane-Free Electrolyser (\"MFE\") for the production of hydrogen, is pleased to announce that it has entered into a Technology Cooperation Agreement (the \"Agreement\") with Bentec GmbH, an operating company entity of Kenera Energy Solutions (\"Kenera\").\n \n \n Kenera is a newly formed business unit within leading drilling, engineering and technology company KCA Deutag Group. Kenera has been formed as the platform from which the KCA Deutag Group shall grow its offering within hydrocarbon and energy transition markets and is a significant investor in CPH2.\n \n \n \n Highlights:\n \n \n \n •\n Pursuant to the terms of the Agreement, Kenera will manufacture up to 30 MFE220 units for CPH2 at its manufacturing facility in Germany.\n \n \n •\n In addition, CPH2 has granted Kenera a non-exclusive license to sell and manufacture CPH2 products in Germany, Scotland, Azerbaijan, Denmark and Norway up to a maximum of 150 MFE units per annum.\n \n \n •\n CPH2 has also granted Kenera an exclusive license to sell and manufacture CPH2 products across the Middle East up to a maximum level of 2GW (including Oman, Saudi Arabia, United Arab Emirates, Qatar, Kuwait and Iraq).\n \n \n The Agreement brings together CPH2's innovative MFE technology, which uses cryogenics to separate oxygen from hydrogen, and Kenera's international client base and industry-leading manufacturing capabilities.\n \n \n The manufacturing arrangements set out in the Agreement will allow an acceleration of the roll out of the Company's technology as the market for hydrogen grows rapidly.\n \n \n The licensing arrangements, which will be effective for a period of ten years following the...